Sigma-1 and Sigma-2 Receptors Are Expressed in a Wide Variety of Human and Rodent Tumor Cell Lines

Cancer Research

Volumn 55, Issue 2, 1995, Pages 408-413

  Vilner, Bertold J ^a   John, Christy S ^b   Bowen, Wayne D ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BIS(2 METHYLPHENYL)GUANIDINE; DEXTRALLORPHAN; HALOPERIDOL; PENTAZOCINE; RECEPTOR SUBTYPE; SIGMA OPIATE RECEPTOR;

ANIMAL CELL; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER DIAGNOSIS; DIAGNOSTIC VALUE; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MELANOMA; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; RECEPTOR DENSITY;

ADENOCARCINOMA; ANIMAL; BINDING, COMPETITIVE; BREAST NEOPLASMS; CARCINOMA, INFILTRATING DUCT; GLIOBLASTOMA; GUANIDINES; HALOPERIDOL; HUMAN; LEUKEMIA; LUNG NEOPLASMS; MALE; MELANOMA; MICE; NEUROBLASTOMA; PENTAZOCINE; PROSTATIC NEOPLASMS; RECEPTORS, SIGMA; TUMOR CELLS, CULTURED;

EID: 0028795145     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Walker, J. M., Bowen, W. D., Walker, F. O. Matsumoto, R. R., de Costa, B. R., and Rice, K. C. Sigma receptors: biology and function. Pharmacol. Rev., 42: 355–402, 1990.
2. Itzhak Y., and Stein, I. Sigma binding sites in the brain: an emerging concept for multiple sites and their relevance for psychiatric disorders. Life Sci., 47:1073–1081, 1990.
3. Su, T-P. Sigma receptors: putative links between nervous, endocrine, and immune systems. Eur. J. Biochem., 200: 633–642, 1990.
4. Su, T-P. Delineating biochemical and functional properties of sigma receptors: emerging concepts. Crit. Rev. Neurobiol., 7: 187–203, 1993.
5. Ferris, C. D., Hirsh, D. J., Brooks, B. P., and Snyder, S. H. Sigma receptors: from molecule to man. J. Neurochem., 57: 729–737, 1991.
6. Bowen, W. D. Biochemical pharmacology of sigma receptors. In: T. W. Stone (ed.), Aspects of Synaptic Transmission, Vol. II: Acetylcholine, Sigma Receptors, CCK and Eicosanoids, Neurotoxins, pp. 113–136. London: Taylor and Francis, 1993.
7. Debonnel, G. Current hypotheses on sigma receptors and their physiological role: possible implications in psychiatry. J. Psychiatr. Neurosci., 18: 157–172, 1993.
8. Hellewell, S. B., and Bowen, W. D. A sigma-like binding site in rat pheochromocy-toma (PC 12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res., 527: 244–253, 1990.
9. 3H]1,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and psuedoallosteric modulation by sigma ligands. Mol. Pharmacol., 39: 222–232, 1991.
10. Quirion, R., Bowen, W. D., Itzhak, Y., Junien, J. L., Musacchio, J. M., Rothman, R. B., Su, T-P., Tam, S. W., and Taylor, D. P. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci., 13: 85–86, 1992.
11. 3H](+)-Pentazocine: a potent and highly selective benzomorphan-based probe for sigma-1 receptors. Mol. Neuropharmacol., 3: 117–126, 1993.
12. EH Paolo, L., Carroll, F. I., Abraham, P., Bai, X., Parham, K., Mascarella, S. W., Zhang, X., Wallace, P., Walker, J. M., and Bowen, W. D. N-Substituted derivatives of normetazocine: differentiation of sigma-1 and sigma-2 receptors. Soc. Neurosci. Abstr., 17: 814, 1991.
13. Vilner, B. J., and Bowen, W. D. Characterization of sigma-like binding sites of NB41A3, S-20Y, and N1E-115 neuroblastomas, C6 glioma, and NG108–15 neuroblastoma-glioma hybrid cells: Further evidence for sigma-2 receptors. In: J. M. Kamenka and E. F. Domino (eds.), Multiple Sigma and PCP Receptor Ligands:Mechanisms for Neuromodulation and Neuroprotection?, pp. 341–353. Ann Arbor, MI: NPP Books, 1992.
14. Hellewell, S. B., Bruce, A., Feinstein, G., Orringer, J., Williams, W., and Bowen, W. D. Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol., Mol. Pharmacol. Sect., 268: 9–18, 1994.
15. Kushner, L., Zukin, S. R., and Zukin, R. S. Characterization of opioid, sigma, and phencyclidine receptors in the neuroblastoma-brain hybrid cell line NCB-20. Mol. Pharmacol., 34: 689–694, 1988.
16. Wu, X-Z., Bell, J. A., Spivak, C. E., London, E. D., and Su, T-P. Electrophysiological and binding studies on intact NCB-20 cells suggest presence of low affinity sigma receptor. J. Pharmacol. Exp. Ther., 257: 351–359, 1991.
17. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265–271, 1951.
18. Cheng, Y-C., and Prusoff, W. H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (150) of an enzymatic reaction. Biochem. Pharmacol., 22: 3099–3108, 1973.
19. Thomas, G. E., Szucs, M., Mamone, J. Y., Bern, W. T., Rush, M. D., Johnson, F. E., and Coscia, C. J. Sigma and opioid receptors in human brain tumors. Life Sci., 46: 1279–1286, 1990.
20. Bern, W. T., Thomas, G. E., Mamone, J. Y., Homan, S. M., Levy, B. K., Johnson, F. E., and Coscia, C. J. Overexpression of sigma receptors in nonneural human tumors. Cancer Res., 57: 6558–6562, 1991.
21. Bowen, W. D., Vilner, B. J., and de Costa, B. R. Sigma receptor-mediated changes in morphology, division, and viability of C6 glioma cells. Soc. Neurosci. Abstr., 19: 420, 1993.
22. Vilner, B. J., and Bowen, W. D. Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. Eur. J. Pharmacol., 244: 199–201, 1993.
23. Vilner, B. J., de Costa, B. R., and Bowen, W. D. Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J. Neurosci., 75: 117–134, 1995.
24. John, C. S., Bowen, W. D., Saga, T., Kinuyam S., Vilner, B. J., Baumgold, J., Paik, C. H., Reba, R. C., Neumann, R. D., Vanna, V. M., and McAfee, J. G. A new malignant melanoma imaging agent: synthesis, characterization, in vitro binding and biodistribution of iodirje-125-(2-piperidmylaminoethyl)4-iodobenzamide. J. Nucl. Med., 34: 2169–2175, 1993.
25. 125I](N-benzylpiperidin-4-yl)4-iodobenzamide, 4-IBP., a new sigma receptor radiopharmaceutical: high affinity binding to MCF-7 breast tumor cells. J. Med. Chem., 37: 1737–1739, 1994.